Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
11 2021
Historique:
received: 25 03 2021
revised: 23 06 2021
accepted: 20 07 2021
pubmed: 28 7 2021
medline: 23 3 2022
entrez: 27 7 2021
Statut: ppublish

Résumé

Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastasizing disease characterized by cystic lung destruction. LAM can exhibit extensive heterogeneity at the molecular, cellular, and tissue levels. However, the molecular similarities and differences among LAM cells and tissue, and their connection to cancer features are not fully understood. By integrating complementary gene and protein LAM signatures, and single-cell and bulk tissue transcriptome profiles, we show sources of disease heterogeneity, and how they correspond to cancer molecular portraits. Subsets of LAM diseased cells differ with respect to gene expression profiles related to hormones, metabolism, proliferation, and stemness. Phenotypic diseased cell differences are identified by evaluating lumican (LUM) proteoglycan and YB1 transcription factor expression in LAM lung lesions. The RUNX1 and IRF1 transcription factors are predicted to regulate LAM cell signatures, and both regulators are expressed in LAM lung lesions, with differences between spindle-like and epithelioid LAM cells. The cancer single-cell transcriptome profiles most similar to those of LAM cells include a breast cancer mesenchymal cell model and lines derived from pleural mesotheliomas. Heterogeneity is also found in LAM lung tissue, where it is mainly determined by immune system factors. Variable expression of the multifunctional innate immunity protein LCN2 is linked to disease heterogeneity. This protein is found to be more abundant in blood plasma from LAM patients than from healthy women. IMPLICATIONS: This study identifies LAM molecular and cellular features, master regulators, cancer similarities, and potential causes of disease heterogeneity.

Identifiants

pubmed: 34312290
pii: 1541-7786.MCR-21-0220
doi: 10.1158/1541-7786.MCR-21-0220
pmc: PMC8568632
mid: NIHMS1729426
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1840-1853

Subventions

Organisme : Intramural NIH HHS
ID : ZIA HL002541
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Am J Respir Cell Mol Biol. 2005 Sep;33(3):227-30
pubmed: 15994429
Mech Dev. 2001 Dec;109(2):413-7
pubmed: 11731260
Am J Surg Pathol. 1993 Nov;17(11):1092-102
pubmed: 8214254
Mol Cell Biol. 2007 Aug;27(16):5746-64
pubmed: 17562867
Leukemia. 2007 Dec;21(12):2495-505
pubmed: 17898786
Annu Rev Nutr. 2017 Aug 21;37:103-130
pubmed: 28628361
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Mol Cancer. 2014 Sep 27;13:223
pubmed: 25261936
Cancer Epidemiol. 2019 Aug;61:154-156
pubmed: 31260937
Development. 2018 Jan 8;145(1):
pubmed: 29311260
Nat Genet. 2019 Mar;51(3):481-493
pubmed: 30804560
Am J Respir Cell Mol Biol. 2018 Dec;59(6):723-732
pubmed: 30095976
Chest. 2019 Dec;156(6):1062-1067
pubmed: 31437431
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90
pubmed: 10823953
J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):75-91
pubmed: 26390871
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669930
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W245-52
pubmed: 17576675
Elife. 2014 Nov 21;3:e03881
pubmed: 25415051
Sci Rep. 2017 Jun 14;7(1):3493
pubmed: 28615679
N Engl J Med. 2011 Apr 28;364(17):1595-606
pubmed: 21410393
Am J Respir Cell Mol Biol. 2017 Aug;57(2):174-183
pubmed: 28314106
Cancers (Basel). 2018 Dec 21;11(1):
pubmed: 30583472
Respir Res. 2018 May 8;19(1):83
pubmed: 29739412
Endocrinology. 2016 Sep;157(9):3374-83
pubmed: 27409646
J Histochem Cytochem. 2004 Dec;52(12):1537-42
pubmed: 15557209
Am J Respir Crit Care Med. 2012 Dec 15;186(12):1210-2
pubmed: 23250499
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2635-40
pubmed: 19202070
Mol Pharmacol. 2009 Oct;76(4):766-77
pubmed: 19596836
Nat Commun. 2020 Nov 6;11(1):5640
pubmed: 33159078
J Proteome Res. 2008 Apr;7(4):1481-9
pubmed: 18311905
J Pathol. 2016 Jul;239(3):274-85
pubmed: 27038000
Cell. 2011 Mar 18;144(6):986-98
pubmed: 21414488
Annu Rev Med. 2017 Jan 14;68:69-83
pubmed: 28099079
Am J Respir Crit Care Med. 2020 Sep 15;202(6):853-865
pubmed: 32392078
Nat Genet. 2020 Nov;52(11):1208-1218
pubmed: 33128048
Front Oncol. 2020 Dec 23;10:605097
pubmed: 33425761
Oncogene. 2005 Sep 8;24(40):6080-9
pubmed: 15897870
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Front Psychol. 2013 Oct 02;4:700
pubmed: 24109465
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genes Dev. 2005 Jul 15;19(14):1715-22
pubmed: 16024660
Am J Respir Cell Mol Biol. 2015 Jul;53(1):96-104
pubmed: 25474372
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Hum Pathol. 1997 Sep;28(9):1071-8
pubmed: 9308732
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Pathol Clin Res. 2020 Jul;6(3):215-226
pubmed: 32352655
Am J Respir Crit Care Med. 2020 Nov 15;202(10):1373-1387
pubmed: 32603599
Lancet Respir Med. 2013 Aug;1(6):445-52
pubmed: 24159565
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
PLoS One. 2015 Jul 13;10(7):e0132546
pubmed: 26167915
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Cancer Res. 2017 Oct 15;77(20):5491-5502
pubmed: 28830860
J Clin Invest. 2012 Nov;122(11):3807-16
pubmed: 23114603
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Am J Clin Pathol. 1990 May;93(5):609-14
pubmed: 2183584
Hum Pathol. 1991 Jul;22(7):727-8
pubmed: 2071116
J Biol Chem. 2014 Feb 28;289(9):5960-9
pubmed: 24391115
Eur Respir J. 2010 Jan;35(1):14-26
pubmed: 20044458
J Immunol. 2009 Feb 1;182(3):1270-7
pubmed: 19155472
Arch Pathol Lab Med. 1994 Jul;118(7):732-4
pubmed: 8024410
N Engl J Med. 2006 Sep 28;355(13):1345-56
pubmed: 17005952
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
Nat Commun. 2020 Jan 30;11(1):619
pubmed: 32001681
Thorax. 2018 Apr;73(4):369-375
pubmed: 28993539
Horm Cancer. 2014 Oct;5(5):284-98
pubmed: 25069840
Chest. 2019 Aug;156(2):298-307
pubmed: 31034819
Expert Rev Respir Med. 2018 Feb;12(2):95-102
pubmed: 29171770
Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26
pubmed: 18094094
Am J Surg Pathol. 1989 Sep;13(9):803-7
pubmed: 2764227
Breast Cancer Res Treat. 2016 Feb;156(1):195-201
pubmed: 26951504
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
BMC Cancer. 2007 Dec 11;7:223
pubmed: 18070364
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Oncogene. 2017 May 11;36(19):2737-2749
pubmed: 27991928
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61
pubmed: 27628078

Auteurs

Roderic Espín (R)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Alexandra Baiges (A)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Eline Blommaert (E)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Carmen Herranz (C)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Antonio Roman (A)

Lung Transplant Unit, Pneumology Service, Lymphangioleiomyomatosis Clinic, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.

Berta Saez (B)

Lung Transplant Unit, Pneumology Service, Lymphangioleiomyomatosis Clinic, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.

Julio Ancochea (J)

Pneumology Service, University Hospital La Princesa, La Princesa Research Institute (IIS-IP), Madrid, Spain.

Claudia Valenzuela (C)

Pneumology Service, University Hospital La Princesa, La Princesa Research Institute (IIS-IP), Madrid, Spain.

Piedad Ussetti (P)

Pneumology Service, University Hospital Clínica Puerta del Hierro, Majadahonda, Madrid, Spain.

Rosalía Laporta (R)

Pneumology Service, University Hospital Clínica Puerta del Hierro, Majadahonda, Madrid, Spain.

José A Rodríguez-Portal (JA)

Medical-Surgical Unit of Respiratory Diseases, University Hospital Virgen del Rocío, Institute of Biomedicine of Seville (IBiS), Seville, Spain.
Biomedical Research Network Centre in Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Coline H M van Moorsel (CHM)

Interstitial Lung Disease (ILD) Center of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.

Joanne J van der Vis (JJ)

Interstitial Lung Disease (ILD) Center of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.

Marian J R Quanjel (MJR)

Interstitial Lung Disease (ILD) Center of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.

Anna Villar-Piqué (A)

Neuroscience Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Biomedical Research Network Centre in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Daniela Diaz-Lucena (D)

Neuroscience Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Biomedical Research Network Centre in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Franc Llorens (F)

Neuroscience Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Biomedical Research Network Centre in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, Göttingen, Germany.

Álvaro Casanova (Á)

Pneumology Service, University Hospital of Henares, University Francisco de Vitoria, Coslada, Madrid, Spain.

María Molina-Molina (M)

Biomedical Research Network Centre in Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Interstitial Lung Disease Unit, Department of Respiratory Medicine, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Mireya Plass (M)

Program for Advancing Clinical Translation of Regenerative Medicine of Catalonia, P-CMR[C], L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Gene Regulation of Cell Identity, Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Biomedical Research Network Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain.

Francesca Mateo (F)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Joel Moss (J)

Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.

Miquel Angel Pujana (MA)

ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain. mapujana@iconcologia.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH